Foghorn Therapeutics (FHTX) Liabilities and Shareholders Equity (2019 - 2026)

Foghorn Therapeutics' Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $222.2 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 14.12% year-over-year to $222.2 million; the TTM figure through Mar 2026 stood at $851.5 million (down 27.82% YoY), while the FY2025 annual figure was $198.1 million, down 30.24% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $222.2 million, up from $198.1 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $488.3 million in Q1 2022, with the low at $198.1 million in Q4 2025.
• The 5-year median for Liabilities and Shareholders Equity is $308.4 million (2024), against an average of $316.6 million.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity soared 133.21% in 2022, then plunged 33.53% in 2025.
• Foghorn Therapeutics' Liabilities and Shareholders Equity stood at $404.9 million in 2022, then declined by 29.38% to $285.9 million in 2023, then dropped by 0.68% to $284.0 million in 2024, then plunged by 30.24% to $198.1 million in 2025, then increased by 12.15% to $222.2 million in 2026.
• Business Quant data shows FHTX's Liabilities and Shareholders Equity at $222.2 million in Q1 2026, $198.1 million in Q4 2025, and $205.0 million in Q3 2025.